Long term safety of GnRH agonist therapy in precocious puberty: An evaluation of reproductive function, bone density and body composition

Peter Lee, Lawrence A. Silverman

Research output: Contribution to journalReview articlepeer-review

Abstract

While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.

Original languageEnglish (US)
Pages (from-to)300-305
Number of pages6
JournalPediatric Endocrinology Reviews
Volume4
Issue numberSUPPL. 3
StatePublished - Jun 1 2007

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Long term safety of GnRH agonist therapy in precocious puberty: An evaluation of reproductive function, bone density and body composition'. Together they form a unique fingerprint.

Cite this